
Healthcare Societies Oppose Legal Advocacy for Ivermectin
The IDSA, HIVMA, and SHEA released a statement opposing legal intervention on behalf of ivermectin as a COVID-19 treatment.
The antiparasitic drug
Ivermectin is
Yesterday, the Infectious Diseases Society of America (IDSA), HIV Medicine Association (HIVMA), and Society for Healthcare Epidemiology of America (SHEA) released a joint
The organizations acknowledged the significant and tragic burden of COVID-19, saying this is why precise research into treatments like ivermectin is so imperative. The health associations strongly voiced their opposition to any legal intervention in favor of ivermectin, writing, “Efforts to influence clinical practice through lawsuits, including recent cases ordering hospitals to treat COVID-19 patients with ivermectin, could expose patients to serious harm and undermine the evaluation of COVID-19 treatments.”
IDSA, HIVMA, and SHEA emphasized that the US Food and Drug Administration (FDA) takes care to review all medical research in a safe and timely fashion. “FDA is considered the global gold standard for safety and effectiveness review of medical products,” they wrote, “and we rely upon FDA expertise now more than ever.”
The societies concluded their statement by noting that the IDSA’s committee of expert infectious diseases clinicians, pharmacists and guideline specialists recommended against the use of ivermectin to treat COVID-19. The panel assessed all available research regarding ivermectin in COVID-19 patients and found the certainty of evidence extremely low.
Studies on the effectiveness of treating COVID-19 with ivermectin have yielded mixed results, but
Currently, ivermectin is
Newsletter
Stay ahead of emerging infectious disease threats with expert insights and breaking research. Subscribe now to get updates delivered straight to your inbox.

















































































































































































































































































